Published 18 hours ago • loading... • Updated 18 hours ago
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
Rosen Law Firm says investors may seek lead plaintiff status after claims ARS misled them about Neffy insurance coverage with CVS Caremark.
The Rosen Law Firm reminds investors of Aardvark Therapeutics, Inc. securities of the October 13, 2026, lead plaintiff deadline for the ongoing securities fraud lawsuit covering February 13, 2025, through May 14, 2026.
According to the lawsuit, Aardvark failed to disclose that ARD-101 was less safe than promised, allegedly overstating the company's clinical, regulatory, and commercial prospects during the Class Period.
When true details regarding drug safety entered the market, investors suffered damages because defendants' public statements were materially false and misleading at all relevant times.
Interested investors may contact Phillip Kim, Esq. at The Rosen Law Firm toll-free at 866-767-3653 or email case@rosenlegal.com to join the class action.
Absent class members remain represented by the Court until a class is certified, meaning individuals need not retain counsel or serve as lead plaintiff to share in potential recoveries.